FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973

Andreas R. Baudy(Gene Therapy Laboratory), Simon‐Peter Williams

EJNMMI Research

May 31, 2012

10.1186/2191-219x-2-22

Cited by 62

Related Papers

No related papers found

Powered by citation graph analysis